Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Prostate Cancer Recurrent 1Glioblastoma 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × TEMPOL-H × Clear all
NCT04876755 2021-05-06

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04874506 2021-05-05

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡